Several analysts have recently updated their ratings and price targets for BioLineRx (NASDAQ: BLRX):

  • 9/27/2017 – BioLineRx was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “
  • 9/26/2017 – BioLineRx had its “buy” rating reaffirmed by analysts at HC Wainwright.
  • 9/21/2017 – BioLineRx was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “
  • 9/12/2017 – BioLineRx had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $3.00 price target on the stock.
  • 9/7/2017 – BioLineRx was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “
  • 8/24/2017 – BioLineRx was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 8/22/2017 – BioLineRx was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “
  • 8/14/2017 – BioLineRx was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “
  • 8/9/2017 – BioLineRx was given a new $3.00 price target on by analysts at Roth Capital. They now have a “buy” rating on the stock.
  • 8/9/2017 – BioLineRx was given a new $4.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 8/8/2017 – BioLineRx was given a new $3.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock.
  • 8/4/2017 – BioLineRx is now covered by analysts at Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $3.00 price target on the stock.

Shares of BioLineRx Ltd. (NASDAQ:BLRX) opened at 1.15 on Tuesday. The company’s market cap is $109.96 million. BioLineRx Ltd. has a 52 week low of $0.80 and a 52 week high of $1.42. The company’s 50-day moving average price is $1.09 and its 200 day moving average price is $0.96.

BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). On average, equities analysts forecast that BioLineRx Ltd. will post ($0.24) EPS for the current fiscal year.

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Receive News & Ratings for BioLineRx Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.